Verdiva Bio Limited raised $411M in a Series A funding led by Forbion and General Atlantic to develop innovative therapies for obesity and cardiometabolic disorders.
Verdiva Bio Limited raised $411M in a Series A funding led by Forbion and General Atlantic to develop innovative therapies for obesity and cardiometabolic disorders.
01/09/25, 7:09 AM
Location
londonMoney raised
$411 million
Industry
biopharma
therapeutics
pharmaceutical
biotechnology
health care
Round Type
series a
Investors
Lyfe Capital, Lilly Asia Ventures, Logos Capital, Orbi Med, Ra Capital Management, General Atlantic, Forbion
Verdiva Bio Limited announced its launch as a clinical-stage biopharmaceutical company with an oversubscribed Series A financing of $411M. The funding will be used to advance a portfolio of next-generation oral and injectable treatments aimed at addressing obesity and related disorders.
Company Info
Location
london, england, united kingdom
Additional Info
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide.